-
Electronic (PDF)
-
Site License
-
Enterprisewide
M et P Pharma AG - Product Pipeline Review - 2012
Global Markets Direct, July 2012, Pages: 23
M et P Pharma AG – Product Pipeline Review – 2012
Summary
Global Market Direct’s pharmaceuticals report, “M et P Pharma AG - Product Pipeline Review - 2012” provides data on the M et P Pharma AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, M et P Pharma AG’s corporate website, SEC filings, investor presentations and featured press releases, both from M et P Pharma AG and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- M et P Pharma AG - Brief M et P Pharma AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of M et P Pharma AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of M et P Pharma AG with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the M et P Pharma AG’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate M et P Pharma AG’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of M et P Pharma AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the M et P Pharma AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with M et P Pharma AG.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of M et P Pharma AG and identify potential opportunities in those areas.
Keywords
Current R&D Portfolio of M et P Pharma AG; M et P Pharma AG - Key Therapeutics; M et P Pharma AG - Pipeline Overview and Promising Molecules; M et P Pharma AG - News; M et P Pharma AG - Latest Updates; M et P Pharma AG - Pipeline; M et P Pharma AG - Discontinued/Dormant Projects
2
List of Tables 3
List of Figures 3
M et P Pharma AG Snapshot 4
M et P Pharma AG Overview 4
Key Information 4
Key Facts 4
M et P Pharma AG – Research and Development Overview 5
Key Therapeutic Areas 5
M et P Pharma AG – Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products – Monotherapy 8
M et P Pharma AG – Pipeline Products Glance 9
M et P Pharma AG Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
M et P Pharma AG – Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
M et P Pharma AG – Drug Profiles 12
DopaMat 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
Nasobol 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Noseafix 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
PregnenoMat 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
ProgestoMat 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
M et P Pharma AG – Pipeline Analysis 17
M et P Pharma AG – Pipeline Products by Therapeutic Class 17
M et P Pharma AG – Pipeline Products By Target 18
M et P Pharma AG – Pipeline Products by Route of Administration 19
M et P Pharma AG – Pipeline Products By Mechanism of Action 20
M et P Pharma AG – Locations And Subsidiaries 21
Head Office 21
Appendix 22
Methodology 22
Coverage 22
Secondary Research 22
Primary Research 22
Expert Panel Validation 22
Contact Us 23
Disclaimer 23
List of Tables
M et P Pharma AG, Key Information 4
M et P Pharma AG, Key Facts 4
M et P Pharma AG – Pipeline by Indication, 2012 6
M et P Pharma AG – Pipeline by Stage of Development, 2012 7
M et P Pharma AG – Monotherapy Products in Pipeline, 2012 8
M et P Pharma AG – Phase II, 2012 9
M et P Pharma AG – Phase I, 2012 10
M et P Pharma AG – Pre-Clinical, 2012 11
M et P Pharma AG – Pipeline By Therapeutic Class, 2012 17
M et P Pharma AG - Pipeline By Target, 2012 18
M et P Pharma AG – Pipeline By Route of Administration, 2012 19
M et P Pharma AG – Pipeline Products By Mechanism of Action, 2012 20
List of Figures
M et P Pharma AG – Pipeline by Indication, 2012 6
M et P Pharma AG – Pipeline by Stage of Development, 2012 7
M et P Pharma AG – Monotherapy Products in Pipeline, 2012 8
M et P Pharma AG – Pipeline By Therapeutic Class, 2012 17
M et P Pharma AG - Pipeline By Target, 2012 18
M et P Pharma AG - Pipeline Products By Mechanism of Action, 2012 20
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
